These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15509119)

  • 21. Epoetin dosing and dialysis facility ownership.
    Kliger AS; Nissenson AR
    JAMA; 2007 Aug; 298(8):861-2; author reply 862-3. PubMed ID: 17712067
    [No Abstract]   [Full Text] [Related]  

  • 22. Fluctuations in haemoglobin levels in haemodialysis patients receiving intravenous epoetin alfa or intravenous darbepoetin alfa.
    Walker R; Pussell BA;
    Nephrology (Carlton); 2007 Oct; 12(5):448-51. PubMed ID: 17803467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
    Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
    Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conversion from subcutaneous to intravenous erythropoietin in a hemodialysis population.
    Vercaigne LM; Collins DM; Penner SB
    J Clin Pharmacol; 2005 Aug; 45(8):895-900. PubMed ID: 16027399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epoetin alfa: to give or not to give.
    Dang C; Hudis C; Norton L
    J Natl Cancer Inst; 2013 Jul; 105(14):1001-3. PubMed ID: 23860203
    [No Abstract]   [Full Text] [Related]  

  • 26. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.
    Glaspy J; Bukowski R; Steinberg D; Taylor C; Tchekmedyian S; Vadhan-Raj S
    J Clin Oncol; 1997 Mar; 15(3):1218-34. PubMed ID: 9060566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
    Krivoshiev S; Wizemann V; Czekalski S; Schiller A; Pljesa S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A;
    Adv Ther; 2010 Feb; 27(2):105-17. PubMed ID: 20369312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subcutaneous compared with intravenous epoetin treatment in patients on hemodialysis: one center study.
    Malovrh M; Premru V
    Ther Apher Dial; 2005 Jun; 9(3):233-6. PubMed ID: 15966996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Epoetin alfa on hemostasis in chronic renal failure.
    Tang WW; Stead RA; Goodkin DA
    Am J Nephrol; 1998; 18(4):263-73. PubMed ID: 9653828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful recombinant erythropoietin therapy for a developing anemic newborn with hereditary spherocytosis.
    Hosono S; Hosono A; Mugishima H; Nakano Y; Minato M; Okada T; Takahashi S; Harada K
    Pediatr Int; 2006 Apr; 48(2):178-80. PubMed ID: 16635181
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinicians adjust to latest ESA recommendations.
    Traynor K
    Am J Health Syst Pharm; 2011 Aug; 68(16):1467, 1472, 1474. PubMed ID: 21817075
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized trial on the therapeutic equivalence between Eprex and GerEPO in patients on haemodialysis.
    Goh BL; Ong LM; Sivanandam S; Lim TO; Morad Z;
    Nephrology (Carlton); 2007 Oct; 12(5):431-6. PubMed ID: 17803464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting anemia with erythropoietin during critical illness.
    Cook D; Crowther M
    N Engl J Med; 2007 Sep; 357(10):1037-9. PubMed ID: 17804850
    [No Abstract]   [Full Text] [Related]  

  • 36. Effectiveness of a pharmacist-implemented anemia management protocol in an outpatient hemodialysis unit.
    To LL; Stoner CP; Stolley SN; Buenviaje JD; Ziegler TW
    Am J Health Syst Pharm; 2001 Nov; 58(21):2061-5. PubMed ID: 11715828
    [No Abstract]   [Full Text] [Related]  

  • 37. Predicting the hematopoietic response to recombinant human erythropoietin (Epoetin alfa) in the treatment of the anemia of cancer.
    Adamson JW; Ludwig H
    Oncology; 1999; 56(1):46-53. PubMed ID: 9885377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous vitamin C for erythropoietin resistance.
    Meléndez O
    Semin Dial; 2000; 13(5):335-6. PubMed ID: 11014698
    [No Abstract]   [Full Text] [Related]  

  • 39. Switching from i.v. to s.c. epoetin in hemodialysis patients.
    Knauss MD; Walton T; Macon EJ
    Am J Health Syst Pharm; 2002 Sep; 59(18):1783-4. PubMed ID: 12298119
    [No Abstract]   [Full Text] [Related]  

  • 40. Erythropoiesis stimulating agents: a personal journey.
    Leyland-Jones B
    J Natl Cancer Inst; 2013 Jul; 105(14):999-1001. PubMed ID: 23860202
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.